Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients.
- Author:
Wei-bin HUANG
1
;
Guang-yu YAO
;
Min-feng LIU
;
Rui-ting CHEN
;
Lu-jia CHEN
;
Jian-yu DONG
;
Fan GU
;
Zhao-ze GUO
;
Chang-sheng YE
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Anthracyclines; adverse effects; therapeutic use; Antibiotics, Antineoplastic; therapeutic use; Biomarkers; blood; Breast Neoplasms; drug therapy; Cardiotoxins; adverse effects; Female; Humans; Middle Aged; Myocardium; metabolism; Troponin I; blood; Young Adult
- From: Journal of Southern Medical University 2011;31(6):1047-1050
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the value of cardiac troponin I (CTnI) measurement in predicting anthracycline-induced cardiotoxicity in patients with breast cancer.
METHODSThis study was conducted among 186 breast cancer patients receiving anthracycline-based chemotherapy. Serum cTnI concentrations before and after each cycle of the chemotherapy and the left ventricular ejection fraction (LVEF) before and at the 2nd, 4th and 6th months of the treatment were recorded. According to serum cTnI concentration, the patients were divided into CTnI+ group (with serum CTnI concentration of no less than 0.1 ng/ml, n=60) and CTnI- (<0.1 ng/ml) group (n=126).
RESULTSNo patients in this series experienced cardiac heart failure (CHF). The number of patients with a LVEF reduction by over 10% from the baseline was 16 (26.7%) in CTnI+ group, as compared to 7 (5.6%) in CTnI- group, showing a significant difference between the two groups (P<0.01).
CONCLUSIONCTnI can be a useful marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.
